Post-earnings recap
Reported
Tue, May 6, 2025
EPS actual
$-0.19
EPS est.
$-0.50
EPS surprise
+61.77%
1-day move
-5.13%
Protagonist Therapeutics reported a narrower loss than expected, which is a positive sign for investors. However, the stock fell by 5.1%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future direction without clear financial expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.19 | N/A | +61.77% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about the company's future, citing progress in key areas. They are focused on upcoming data that could impact their strategy.
Management highlighted ongoing progress in clinical trials.
They emphasized the importance of upcoming data releases.
There was a focus on maintaining operational efficiency.
Est. EPS
—
Est. Rev
—
Impl. Move
—